Which has higher earnings & valuation, ALVO or ACIU?

Alvotech has higher revenue and earnings than AC Immune. Alvotech is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alvotech $588.90M 1.79 $27.92M -$0.25 N/A AC Immune $4.31M 53.95 -$85.03M -$0.82 N/A

Is ALVO or ACIU more profitable?

Alvotech has a net margin of -14.36% compared to AC Immune's net margin of -1,788.02%. Alvotech's return on equity of -11.92% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Alvotech -14.36% -11.92% -7.59% AC Immune -1,788.02% -125.26% -40.85%

Is DBVT or ACIU more profitable?

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% AC Immune -1,788.02% -125.26% -40.85%

AC Immune (ACIU) Competitors

$2.28 +0.04 (+1.56%)

As of 10:27 AM Eastern

Compare

ACIU vs. ALVO, JANX, ANRO, DBVT, and SLDB

Should you buy AC Immune stock or one of its competitors? MarketBeat compares AC Immune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AC Immune include Alvotech (ALVO), Janux Therapeutics (JANX), Alto Neuroscience (ANRO), DBV Technologies (DBVT), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does AC Immune compare to Alvotech?

Alvotech (NASDAQ:ALVO) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Alvotech presently has a consensus price target of $7.60, suggesting a potential upside of 117.45%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 228.23%. Given AC Immune's stronger consensus rating and higher probable upside, analysts clearly believe AC Immune is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Alvotech had 1 more articles in the media than AC Immune. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for AC Immune. Alvotech's average media sentiment score of 0.53 beat AC Immune's score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company	Overall Sentiment
Alvotech	Positive
AC Immune	Neutral

Alvotech has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

51.4% of AC Immune shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alvotech has a net margin of -14.36% compared to AC Immune's net margin of -1,788.02%. Alvotech's return on equity of -11.92% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
AC Immune	-1,788.02%	-125.26%	-40.85%

Alvotech has higher revenue and earnings than AC Immune. Alvotech is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.79	$27.92M	-$0.25	N/A
AC Immune	$4.31M	53.95	-$85.03M	-$0.82	N/A

Summary

Alvotech and AC Immune tied by winning 8 of the 16 factors compared between the two stocks.

How does AC Immune compare to Janux Therapeutics?

AC Immune (NASDAQ:ACIU) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Janux Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Janux Therapeutics' return on equity of -12.93% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Janux Therapeutics	N/A	-12.93%	-12.23%

51.4% of AC Immune shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AC Immune has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	53.95	-$85.03M	-$0.82	N/A
Janux Therapeutics	$10M	98.61	-$113.62M	-$1.84	N/A

AC Immune presently has a consensus target price of $7.50, suggesting a potential upside of 228.23%. Janux Therapeutics has a consensus target price of $38.08, suggesting a potential upside of 135.50%. Given AC Immune's higher probable upside, equities analysts clearly believe AC Immune is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Janux Therapeutics had 2 more articles in the media than AC Immune. MarketBeat recorded 2 mentions for Janux Therapeutics and 0 mentions for AC Immune. Janux Therapeutics' average media sentiment score of 0.88 beat AC Immune's score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AC Immune	Neutral
Janux Therapeutics	Positive

AC Immune has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market.

Summary

Janux Therapeutics beats AC Immune on 12 of the 16 factors compared between the two stocks.

How does AC Immune compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

51.4% of AC Immune shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alto Neuroscience has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Alto Neuroscience's return on equity of -47.22% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
AC Immune	-1,788.02%	-125.26%	-40.85%

Alto Neuroscience has higher earnings, but lower revenue than AC Immune. Alto Neuroscience is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
AC Immune	$4.31M	53.95	-$85.03M	-$0.82	N/A

Alto Neuroscience has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

In the previous week, Alto Neuroscience had 6 more articles in the media than AC Immune. MarketBeat recorded 6 mentions for Alto Neuroscience and 0 mentions for AC Immune. Alto Neuroscience's average media sentiment score of 0.49 beat AC Immune's score of 0.00 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
AC Immune	Neutral

Alto Neuroscience presently has a consensus price target of $35.25, suggesting a potential upside of 30.44%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 228.23%. Given AC Immune's higher probable upside, analysts clearly believe AC Immune is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Alto Neuroscience beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does AC Immune compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

AC Immune has lower revenue, but higher earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	149.81	-$146.95M	-$3.51	N/A
AC Immune	$4.31M	53.95	-$85.03M	-$0.82	N/A

DBV Technologies has a beta of -0.95, suggesting that its stock price is 195% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, DBV Technologies had 19 more articles in the media than AC Immune. MarketBeat recorded 19 mentions for DBV Technologies and 0 mentions for AC Immune. DBV Technologies' average media sentiment score of 0.07 beat AC Immune's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
DBV Technologies	Neutral
AC Immune	Neutral

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
AC Immune	-1,788.02%	-125.26%	-40.85%

DBV Technologies presently has a consensus price target of $48.50, suggesting a potential upside of 239.87%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 228.23%. Given DBV Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe DBV Technologies is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

DBV Technologies beats AC Immune on 10 of the 17 factors compared between the two stocks.

How does AC Immune compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Solid Biosciences' average media sentiment score of 0.00 equaled AC Immune'saverage media sentiment score.

Company	Overall Sentiment
Solid Biosciences	Neutral
AC Immune	Neutral

Solid Biosciences currently has a consensus target price of $17.11, indicating a potential upside of 102.98%. AC Immune has a consensus target price of $7.50, indicating a potential upside of 228.23%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Solid Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

AC Immune has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
AC Immune	$4.31M	53.95	-$85.03M	-$0.82	N/A

Solid Biosciences has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Solid Biosciences' return on equity of -73.42% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
AC Immune	-1,788.02%	-125.26%	-40.85%

Summary

Solid Biosciences and AC Immune tied by winning 7 of the 14 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$231.53M	$3.64B	$6.80B	$12.37B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-2.77	20.71	27.09	24.07
Price / Sales	53.95	302.58	520.26	91.86
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	4.23	7.99	10.64	6.20
Net Income	-$85.03M	$23.81M	$3.60B	$331.63M
7 Day Performance	-5.19%	-1.92%	-1.41%	-1.54%
1 Month Performance	-4.79%	1.88%	0.97%	-1.17%
1 Year Performance	9.86%	43.58%	24.23%	17.81%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	2.2174 of 5 stars	$2.29 +1.6%	$7.50 +228.2%	+8.7%	$231.53M	$4.31M	N/A	140
ALVO Alvotech	4.0148 of 5 stars	$3.27 -3.4%	$7.60 +132.8%	-60.5%	$987.22M	$588.90M	N/A	1,460	Positive News Gap Down
JANX Janux Therapeutics	3.8416 of 5 stars	$15.96 -1.1%	$38.08 +138.6%	-39.2%	$976.29M	$10M	N/A	30	Positive News
ANRO Alto Neuroscience	2.464 of 5 stars	$27.73 -1.1%	$35.25 +27.1%	+835.3%	$976.20M	N/A	N/A	N/A	Analyst Upgrade
DBVT DBV Technologies	3.9641 of 5 stars	$16.32 +2.1%	$48.50 +197.2%	+45.7%	$966.31M	$5.64M	N/A	80	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors

ACIU vs. ALVO, JANX, ANRO, DBVT, and SLDB

How does AC Immune compare to Alvotech?

Summary

How does AC Immune compare to Janux Therapeutics?

Summary

How does AC Immune compare to Alto Neuroscience?

Summary

How does AC Immune compare to DBV Technologies?

Summary

How does AC Immune compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AC Immune (ACIU) Competitors

ACIU vs. ALVO, JANX, ANRO, DBVT, and SLDB

How does AC Immune compare to Alvotech?

Do analysts recommend ALVO or ACIU?

Does the media refer more to ALVO or ACIU?

Which has more risk and volatility, ALVO or ACIU?

Do insiders & institutionals hold more shares of ALVO or ACIU?

Is ALVO or ACIU more profitable?

Which has higher earnings & valuation, ALVO or ACIU?

Summary

How does AC Immune compare to Janux Therapeutics?

Is ACIU or JANX more profitable?

Do institutionals & insiders hold more shares of ACIU or JANX?

Which has stronger earnings & valuation, ACIU or JANX?

Do analysts recommend ACIU or JANX?

Does the media prefer ACIU or JANX?

Which has more volatility and risk, ACIU or JANX?

Summary

How does AC Immune compare to Alto Neuroscience?

Do institutionals and insiders hold more shares of ANRO or ACIU?

Is ANRO or ACIU more profitable?

Which has stronger earnings & valuation, ANRO or ACIU?

Which has more volatility & risk, ANRO or ACIU?

Does the media refer more to ANRO or ACIU?

Do analysts recommend ANRO or ACIU?

Summary

How does AC Immune compare to DBV Technologies?

Which has higher earnings and valuation, DBVT or ACIU?

Which has more volatility and risk, DBVT or ACIU?

Do insiders and institutionals have more ownership in DBVT or ACIU?

Does the media refer more to DBVT or ACIU?

Is DBVT or ACIU more profitable?

Do analysts rate DBVT or ACIU?

Summary

How does AC Immune compare to Solid Biosciences?

Do insiders and institutionals hold more shares of SLDB or ACIU?

Does the media refer more to SLDB or ACIU?

Do analysts recommend SLDB or ACIU?

Which has more volatility & risk, SLDB or ACIU?

Which has higher earnings & valuation, SLDB or ACIU?

Is SLDB or ACIU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools